öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£ºÇر¦Àö
ÐÔ±ð£º
ÈËÆøÖ¸Êý£º51

ËùÊôԺУ£º´óÁ¬Ò½¿Æ´óѧ
ËùÊôԺϵ£º
Ö°³Æ£º½ÌÊÚ
µ¼Ê¦ÀàÐÍ£ºË¶µ¼
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÖ×Áöѧ
Ñо¿ÁìÓò£º Ö÷ÒªÖÂÁ¦ÓÚÏû»¯µÀ°©Õï¶ÏºÍÖÎÁÆ£»Ö×Áö²¢·¢Ö¢µÄÁÙ´²ºÍ»ù´¡Ñо¿£»¶ñÐÔÖ×Áö°ÐÏòÖÎÁÆ»úÖƺÍÄÍÒ©Äæת»ú... [Õ¹¿ª]


Ñо¿ÁìÓò£º Ö÷ÒªÖÂÁ¦ÓÚÏû»¯µÀ°©Õï¶ÏºÍÖÎÁÆ£»Ö×Áö²¢·¢Ö¢µÄÁÙ´²ºÍ»ù´¡Ñо¿£»¶ñÐÔÖ×Áö°ÐÏòÖÎÁÆ»úÖƺÍÄÍÒ©Äæת»úÖƵÄÑо¿£»»¯ÁÆÒ©ÎïÏ໥×÷ÓõĻù´¡Ñо¿£»ÖÐÎ÷Ò½½áºÏÖÎÁÆÏû»¯µÀÖ×ÁöµÄ»úÖÆÑо¿ºÍÓ¦Óᣠ[ÊÕÆð]




ͨѶ·½Ê½ :
µç×ÓÓʼþ£ºporyqin@126.com


¸öÈ˼òÊö :
Çر¦Àö£¬ÁôÈÕ²©Ê¿£¬Ö÷ÈÎҽʦ£¬½ÌÊÚ£¬Ë¶Ê¿Éúµ¼Ê¦¡£ÖйúÀÏÄêѧѧ»áÀÏÄêÖ×ÁööλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»áÖ´ÐÐίԱ»áίԱ£¬ÁÉÄþÊ¡¿¹°©Ð­»áµÚÎå½ìÀíÊ»áÀíÊ£¬ÁÉÄþÊ¡¿¹°©Ð­»á»¯ÁÆöλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»á³£ÎñίԱ£¬ÁÉÄþʡϸ°ûÉúÎïѧѧ»áÖ×Áö°ÐÏòÖÎÁÆöλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»á¸±Ö÷ÈÎίԱ£¬ÁÉÄþʡϸ°ûÉúÎïѧѧ»áÖ×Áöϸ°ûÉúÎïѧöλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»á³£ÎñÀíÊ£¬ÁÉÄþÊ¡¿¹°©Ð­»áµÚËĽì´ó³¦°©öλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»á³£ÎñίԱ¡£ÏÖÈÎÁÉÄþÊ¡Ö×ÁöÒ½ÔºÏû»¯µÀÖ×ÁöÄÚ¿Æ£¨ÄÚ¶þ¿Æ£©¿ÆÖ÷ÈΣ¬´óÁ¬Ò½¿Æ´óѧÖ×ÁöѧöλÔÓéÀֵǼÈë¿ÚÏÂÔؽÌÊÚ¡£1988Äê±ÏÒµÓÚ½õÖÝҽѧԺҽÁÆϵ£¬Í¬Äê¾ÍÖ°ÓÚÁÉÄþÊ¡Ö×ÁöÒ½ÔºÄÚ¿Æ¡£1993Äê½úÉýΪÖ÷ÖÎҽʦ£¬2001Äê½úÉýΪ¸±Ö÷ÈÎҽʦ¡£2003Äê×÷Ϊ·ÃÎÊѧÕ߸°ÈÕ±¾¾ÅÖÝ´óѧҽѧÑо¿ÔºÏû»¯µÀÖ×ÁöÄÚ¿Æѧϰ£¬2004ÄêÔÚÈÕ±¾¾ÅÖÝ´óѧҽѧÑо¿ÔºÏû»¯µÀÖ×ÁöÄڿƹ¥¶Á·Ö×ÓÖ×Áöѧ²©Ê¿Ñ§Î»£¬2006Äê»Øµ½ÁÉÄþÊ¡Ö×ÁöÒ½Ôº£¬Í¬Äê½úÉýΪÖ÷ÈÎҽʦ£¬2007Äê»ñ²©Ê¿Ñ§Î»£¬²¢½úÉýΪ¿ÆÖ÷ÈΣ¬2009Äê±»ÆÀΪ˶ʿÉúµ¼Ê¦¡£25ÄêÀ´Ò»Ö±ÖÂÁ¦ÓÚÒÔÏû»¯µÀ°©ÎªÖ÷µÄ¶ñÐÔÖ×ÁöÕï¶ÏºÍÖÎÁÆ£»Ö×Áö²¢·¢Ö¢µÄ»ù´¡Ñо¿£»¶ñÐÔÖ×Áö°ÐÏòÖÎÁÆ»úÖƺÍÄÍÒ©Äæת»úÖƵÄÑо¿£»»¯ÁÆÒ©ÎïÏ໥×÷ÓõĻù´¡Ñо¿¡£ÔÚÈÕ±¾ÁôѧÆÚ¼äÍê³É²¢²ÎÓë¶àÏî¿ÎÌâÑо¿£¬·¢±íSCIÂÛÎÄ10ƪ£¬ÆäÖÐÒÔµÚÒ»×÷Õß·¢±íSCIÂÛÎÄ4ƪ£¬ÀۼƱ»ÒýÓÃ163´Î£¬²¢»ñÈÕ±¾¾ÅÖÝ´óѧҽѧ²¿Í¬´°»á¹ú¼ÊÑо¿Öú³É»ù½ð½±¡£ÔÚ¹úÄÚÖ÷³ÖÊ¡²¿¼¶¿ÆÑпÎÌâ¶àÏÔÚÖÐÎĺËÐÄÆÚ¿¯·¢±í¶àƪÂÛÎÄ£¬²¢²Î±à¡¶³£¼û¶ñÐÔÖ×ÁöÕïÁƹ淶¡·µÈÊé¼®¡£

¿ÆÑй¤×÷ :
ÔÚÑÐÏîÄ¿
1¡¢Öйúҽѧ»á»ù½ð»á¿ÎÌ⣬¡°UGT1A1Ö¸µ¼²»Í¬¼ÁÁ¿¿ªÆÕÍØÁªºÏ·úÄòà×à¤Ò»ÏßÖÎÁÆÍíÆÚ½áÖ±³¦°©µÄÇ°Õ°ÐÔÑо¿¡±£¬ÏîÄ¿¸ºÔðÈË
2¡¢ÁÉÄþÊ¡¿Æ¼¼Ìü×ÊÖúÏîÄ¿£¬¡°µÍ·Ö×Ó¸ÎËØÔ¤·ÀÖ×Áö»¼ÕßѪ˨µÄÁÙ´²Ñо¿¡±£¬ÏîÄ¿¸ºÔðÈË
´ú±íÐÔÎÄÕ£¨* ͨѶ×÷Õߣ©
1. Qin B, Tanaka R, Shibata Y, Arita S, Ariyama H, Kusaba H, Baba E, Harada M, Nakano S.In-vitro schedule-dependent interaction between oxaliplatin and 5-fluorouracil in human gastric cancer cell lines£¬Anticancer Drugs£¬2006 Apr£¬17(4)£º445-53.
2£®Qin B, Tanaka R, Ariyama H, Shibata Y, Arita S, Kusaba H, Baba E, Harada M, Nakano S. In-vitro differential metabolism and activity of 5-fluorouracil between short-term, high-dose and long-term, low-dose treatments in human squamous carcinoma cells£¬Anticancer Drugs£¬2006 Apr£¬17(4)£º439-43.
3£®Qin B, Ariyama H, Baba E, Tanaka R, Kusaba H, Harada M, Nakano S. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells£¬Cancer Chemother Pharmacol, 2006 Nov,58(5):577-84.
4£®Qin B, Kato K, Mitsugi K, Nakamura M, Tanaka R, Baba E, Ariyama H, Kuroiwa T, Harada M, Nakano S.Feasibility study of ambulatory continuous infusion of 5-fluorouracil followed by cisplatin through hepatic artery for metastatic colorectal cancer£¬Cancer Chemother Pharmacol£¬2006Jan£¬57(1)£º114-9.
5. Íõ½¿£¬Ëïºê࣬ÁøÐÇ£¬Çر¦Àö*.ERCC1ºÍTS±í´ï¶Ôθ°©Êõºó»¼ÕßFOLFOX·½°¸¸¨Öú»¯ÁÆÁÆЧµÄÔ¤²â£¬ÊµÓÃÖ×ÁöѧÔÓÖ¾£¬¸åºÅ£ºA13263£¨ÅÅ°æÖУ©.